What is a common treatment for von Willebrand Disease?

Von Willebrand Disease (VWD) is a genetic bleeding disorder characterized by a deficiency or dysfunction of von Willebrand factor, which is crucial for platelet adhesion and aggregation in hemostasis. The treatment primarily focuses on increasing the levels and activity of von Willebrand factor to prevent bleeding episodes.

Desmopressin (DDAVP) is the common treatment for VWD, particularly in type 1 and some cases of type 2. It works by stimulating the release of von Willebrand factor from endothelial cells, leading to an increase in factor VIII levels and improving platelet function. This makes it effective for managing bleeding episodes and preparing for surgical procedures in patients with VWD.

This targeted approach distinguishes DDAVP from other treatment options. Factor VII, while important for clotting, does not directly address the deficiency of von Willebrand factor. Warfarin is an anticoagulant that would not be appropriate for treating a bleeding disorder. Aspirin, which can inhibit platelet aggregation, would worsen bleeding in patients with von Willebrand Disease rather than assist in treatment. Therefore, DDAVP is the appropriate choice for managing von Willebrand Disease effectively.